Core Viewpoint - Xing Tai Chain Group (00399) experienced a significant decline in stock price, dropping over 70% in early trading, with a current price of 0.079 HKD and a trading volume of 7.6626 million HKD [1] Group 1: Stock Performance - The company's stock fell by 66.81% as of the latest report [1] - The trading volume reached 7.6626 million HKD, indicating heightened market activity [1] Group 2: Regulatory Announcement - The company received a letter from the Stock Exchange on November 14, 2025, stating that it failed to maintain sufficient operational levels and asset value to support continued listing [1] - According to Listing Rule 6.01(3), trading of the company's shares will be suspended on November 26, 2025, unless the company applies for a review of this decision [1] - The board of directors has decided to request a review of the decision and is preparing the necessary documentation [1] Group 3: Investor Advisory - The company has informed shareholders and potential investors about its decision to seek a review of the suspension [1] - The outcome of the review by the Listing Committee remains uncertain [1]

经审阅该决定函件，公司董事会已决定要求将该决定提交上市委员会复核，并正在编制相关要求函件。 谨此提醒股东及潜在投资者，公司已决定要求复核该决定，惟上市委员会对有关复核的结果并不明朗。 智通财经APP获悉，星太链集团(00399)早盘跌超70%，截至发稿，跌66.81%，报0.079港元，成交额 766.26万港元。 消息面上，星太链集团今早公告，于2025年11月14日，公司接获联交所的函件，通知公司其作出的决 定，即经考虑联交所可得资料(包括公司的提呈文件)，根据第13.24条的规定，公司未能维持足够的运营 水平和足够价值的资产支持其运营，令其股份得以继续上市，并将根据上市规则第6.01(3)条，于2025年 11月26日暂停公司股份买卖，除非公司根据其在第2B章项下的权利申请复核该决定。 ...

Core Viewpoint - The stock of Star Chain Group experienced a significant drop of over 60% upon opening on November 17, 2025, due to a decision from the Hong Kong Stock Exchange regarding insufficient operational levels and asset value [1] Group 1 - The company received a notice from the Stock Exchange on November 14, 2025, indicating that trading of its shares will be suspended on November 26, 2025 [1] - The board of directors has decided to request a review of this decision by the Listing Committee and is preparing the necessary documentation [1]

Core Viewpoint - Star Chain Group (00399.HK) has received a letter from the Stock Exchange indicating that it has failed to maintain sufficient operational levels and asset value to support its operations, leading to a decision to suspend trading of its shares on November 26, 2025, unless a review is requested [1] Group 1 - The Stock Exchange's decision is based on the company's inability to meet the requirements under Rule 13.24 [1] - The company’s board has decided to request a review of the decision by the Listing Committee and is preparing the necessary documentation [1]

Core Viewpoint - Xing Tai Chain Group (00399) has received a letter from the Stock Exchange indicating that it has failed to maintain sufficient operational levels and asset value to support its operations, leading to a decision to suspend trading of its shares on November 26, 2025, unless a review is requested [1] Summary by Sections - Company Operations - The company has been notified by the Stock Exchange that it does not meet the operational and asset value requirements as per Rule 13.24 [1] - The decision to suspend trading is based on the company's inability to maintain adequate operational levels [1] - Share Trading - Trading of the company's shares will be suspended on November 26, 2025, according to Listing Rule 6.01(3) [1] - The company is preparing a request to have this decision reviewed by the Listing Committee [1] - Investor Communication - The company has informed shareholders and potential investors about the decision and its intention to seek a review [1] - The outcome of the review by the Listing Committee remains uncertain [1]

Core Viewpoint - The company, Star Chain Group (00399), has received a letter from the Stock Exchange indicating that it has failed to maintain sufficient operational levels and asset value to support its operations, leading to a decision to suspend trading of its shares on November 26, 2025, unless a review is requested [1] Group 1 - The Stock Exchange's decision is based on the company's inability to meet the requirements outlined in Rule 13.24 [1] - The company’s board has decided to request a review of the Stock Exchange's decision and is preparing the necessary documentation for this request [1] - The outcome of the review by the Listing Committee remains uncertain [1]

STARCOIN GROUP LIMITED 星太鏈集團有限公司 （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 聯交所根據第13.24條作出之決定 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告由星太鏈集團有限公司（「本公司」，連同其附屬公司，統稱「本集團」）根 據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09條 及香港法例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見上 市規則）作出。 於二零二五年十一月十四日，本公司接獲聯交所之函件（「該函件」），通知本公 司其作出之決定，即經考慮聯交所可得資料（包括本公司的提呈文件），根據第 13.24條的規定，本公司未能維持足夠的運營水平和足夠價值的資產支持其運營， 令其股份得以繼續上市，並將根據上市規則第6.01(3)條，於二零二五年十一月 二十六日暫停本公司股份買賣（「該決定」），除非本公司 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 星太鏈集團有限公司 呈交日期: 2025年11月5日 FF301 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00399 | 說明 | 星太鏈集團 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 茲提述星太鏈集團有限公司（「本公司」）日期為二零二五年十月十三日的公告（「該 公告」），內容有關日期為二零二五年十月十三日有關代幣發行之諒解備忘錄。 除文義另有指明外，本公告所用詞彙與該公告所界定者具有相同涵義。 本公司謹此補充有關代幣發行的資料，本公司將委聘專注於數字資產的香港 法律顧問，以就代幣發行的分類及架構提供意見，包括但不限於所涉及的私隱 考慮及排除代幣分派可能受限制的司法權區股東或替代機制。如有需要，本公 司亦將委聘擁有相關牌照的分銷商或代理協助代幣發行。除非及直至本公司 已取得所有必要意見及確認，指代幣發行在所有方面均符合所有適用法律法規， 否則本公司將不會進行代幣發行。 於本公告日期，本公司正就代幣發行進行法律審核及諮詢，尚未與監管機關展 開任何諮詢。董事會將密切留意事態發展及任何私隱或利益衝突事宜，以確保 在所有時候均妥為遵守所有監管程序。 本公司將於適當時候及倘此事項有任何重大進展 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 STARCOIN GROUP LIMITED 星太鏈集團有限公司 （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 進一步延長最後截止日期 茲提述星太鏈集團有限公司（前稱領航醫藥及生物科技有限公司）（「本公司」） 日期為二零二五年七月十五日、二零二五年七月十六日、二零二五年八月五日、 二零二五年八月二十六日、二零二五年九月十六日及二零二五年十月六日的 公告（統稱「該等公告」），內容有關張彪兵及陳靜按每股認購股份0.3124港元的 認購價分別認購本公司60,000,000股股份及30,000,000股股份。除文義另有規定 外，本公告所用詞彙與該等公告所界定者具有相同涵義。 認購協議B 根據認購協議B（經補充協議B及日期為二零二五年八月五日、二零二五年八月 二十六日、二零二五年九月十六日及二零二五年十月六日的延長函件修訂及 補充），倘先決條件未能於二 ...